Anticancer agent 48
Anticancer agent 48 (compound 48) is a broad spectrum anticancer agent. Anticancer agent 48 inhibits tubulin polymerization. Anticancer agent 48 shows antiproliferative activity. Anticancer agent 48 shows antitumor activity in vivo. Anticancer agent 48 has the potential for the research of solid and hematological tumors.
For research use only. We do not sell to patients.
- CAS No.: 2395009-13-7
- Formula: C26H25N3O4
- Molecular Weight:443.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
27 nM
Compound: 48
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| HT-29 | IC50 |
51 nM
Compound: 48
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| KBM5 | IC50 |
14 nM
Compound: 48
|
Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| KBM5 | IC50 |
16 nM
Compound: 48
|
Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| KU812 cell line | IC50 |
8 nM
Compound: 48
|
Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| MCF7 | IC50 |
14 nM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 96 hrs
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 96 hrs
|
[PMID: 34052717] |
| MCF7 | IC50 |
14 nM
Compound: 48
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay
|
[PMID: 31727471] |
| SW480 | IC50 |
48 nM
Compound: 48
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| SW-620 | IC50 |
28 nM
Compound: 48
|
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| T-24 | IC50 |
12 nM
Compound: 48
|
Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31727471] |
| T98G | IC50 |
36.6 nM
Compound: 48
|
Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 31727471] |
| U-87MG ATCC | IC50 |
30.9 nM
Compound: 48
|
Cytotoxicity against human U87MG cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against human U87MG cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 31727471] |
In Vitro
Anticancer agent 48 (compound 48) inhibits tubulin polymerization and MCF-7 cancer cell growth with IC50s of 0.47 µM and 14 nM, respectively[1].
Anticancer agent 48 shows antiproliferative activity with IC50s of 8, 10, 12, 14, 16 nM for KU812, LAMA84-S, LAMA84-R, KBM5-WT, KBM5-T315I cells, respectively[1].
Anticancer agent 48 shows growth inhibition with IC50s of 12, 31, 37, 221, 56, 27, 51, 48, 28, 12 nM for U343G, U87MG, T98G, SK-N-BE, SK-N-BE(2)-C, HT29, HCT116, SW480, SW620, T24 cell, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8 week-old female BALB/Cnu/nu mice (EZ-2 or T24 cells)[1]
-
Dosage:20 mg/kg
-
Administration:I.p.; every 2 days for 40 days
-
Result:Significantly inhibited cancer cell proliferation, in vivo tumorigenesis, and tumor angiogenesis.
Chemical Information
-
CAS No. 2395009-13-7
-
Molecular Weight 443.49
-
Formula C26H25N3O4
-
SMILES
COC1=CC(C(C2=CN(C=C2C3=CC=C(C=C3)N)C4=CC=CC(N)=C4)=O)=CC(OC)=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)